AGM Statement and Trading Update

CVS, the UK listed veterinary group and a leading provider of veterinary services, is holding its Annual General Meeting at 11.00am today and provides the following update to shareholders ahead of the meeting.

Current Trading

The Board is pleased to report a good start to the financial year with performance in the first four months in line with expectations.

In the four-month period to 31 October 2023, the Group's total sales grew by 11.9%, with like-for-like sales1 increasing by 5.8%, reflecting positive performance across all business areas.

Our Healthy Pet Club preventative care scheme has seen a further increase in membership, with 499,000 members as at 31 October 2023 (31 October 2022: 479,000 members) reflecting an increase of 4.2% over the last twelve months.

In the period we have launched a new Clinical Governance Framework, demonstrating our commitment to driving standards of care across the veterinary profession.

The Group's adjusted EBITDA2 margin remains in line with the prior period at c.19%, reflecting continued investment in support functions and clinical care.

Strong operating cash conversion has supported investment in acquisitions and capital expenditure with leverage3 on a bank test basis remaining in line with management expectations and below 1.0x (30 June 2023: 0.73x). The Group has continued to increase its investment in practice refurbishment, relocations, clinical equipment and technology with £10.9m invested in the year-to-date vs £10.8m in the prior year corresponding period. The Group expects to spend between £30m and £50m in capital expenditure for the full year.

Acquisitions

Australia

The Group has completed a further four small animal first opinion practice acquisitions bringing the total to nine acquisitions comprising eleven practice sites in the financial year to date, for aggregate initial consideration of A$67.6m / £35.6m. The acquisitions made to date, together with our strong pipeline, provide a meaningful platform for our operations in Australia:

United Kingdom

The Group has completed a further two small animal first opinion practice acquisitions in the UK bringing the total to four acquisitions comprising four practice sites, for aggregate initial consideration of £10.1m. The acquisitions were completed following the submission of briefing papers to the Competition and Markets Authority ("CMA").

All Australia and UK acquisitions are performing in line with expectations.

CMA

Following our update in September, we have met with the CMA and responded to a number of questions and information requests. We will continue to support the CMA with their review and look forward to a further update from the CMA in the coming months.

Dividend

As previously announced, and subject to shareholder approval at the AGM, CVS intends to pay a dividend of 7.5 pence per ordinary share on 8 December 2023 to holders on the register as at 3 November 2023. The ex-dividend date was 2 November 2023.

Board appointment update

Following the resignation of the Group's Chair, Richard Connell, due to ill health, we have commenced a formal search to appoint a successor. The board would like to take the opportunity to thank Richard Connell for his considerable contribution as Chair over the past 16 years. In the interim period Deborah Kemp, the Group's Senior Independent Director continues to undertake this role.

Outlook

We continue to focus on the delivery of our well-defined strategy, with our purpose to give the best possible care to animals and our vision to be the veterinary company people most want to work for. We remain committed to investing in our practices and clinical equipment in order to drive quality services and organic growth.

We are delighted with the progress made in Australia in both completed acquisitions and in developing a strong pipeline of opportunities.

Whilst mindful of the wider macro-economic uncertainty, the Group continues to trade in line with full year market expectations and the Group remains well placed to achieve further growth over the longer term and to deliver on our five-year plan.

The Board would like to thank all members of the CVS team for their continued dedication and support.

Notes

• Leverage on a bank test basis is drawn bank debt less cash and cash equivalents, divided by adjusted EBITDA annualised for the effect of acquisitions, including acquisition costs arising from business combinations and excluding share option costs, prior to the adoption of IFRS 16.

CVS Group plc via Camarco

Richard Fairman, CEO

Ben Jacklin, Deputy CEO

Robin Alfonso, CFO

Peel Hunt LLP (Nominated Adviser & Broker) +44 (0)20 7418 8900

Adrian Trimmings / Michael Burke / Andrew Clark / Lalit Bose

Berenberg (Joint Broker) +44 (0)20 3207 7800

Toby Flaux / Ben Wright / James Thompson / Milo Bonser

Camarco (Financial PR)

Geoffrey Pelham-Lane +44 (0)7733 124 226

Ginny Pulbrook +44 (0)7961 315 138